BioMarin & n-Lorem: A New Model for Tackling Rare Genetic Disease

SAN RAFAEL, CA – July 27, 2026

In a move that signals both a major hope for a newly identified patient community and a strategic evolution in rare disease drug development, BioMarin Pharmaceutical Inc. and the non-profit n-Lorem Foundation have announced a landmark collaboration. The partnership aims to develop the first-ever medicine for ReNU syndrome, a serious neurodevelopmental condition only discovered by geneticists in 2024.

The global exclusive license agreement combines BioMarin’s commercial-scale expertise in genetic medicines with n-Lorem’s pioneering work in antisense oligonucleotide (ASO) technology. Together, they will advance an investigational ASO designed to target the underlying genetic cause of ReNU syndrome, a condition for which no approved treatments currently exist.

A Diagnosis Without a Treatment: The World of ReNU Syndrome

For thousands of families, the journey through the world of rare disease is often a long and arduous diagnostic odyssey. The discovery of ReNU syndrome in 2024 by a team led by Dr. Nicola Whiffin at the University of Oxford and Dr. Ernest Turro at the Mt. Sinai Icahn School of Medicine provided a name for a constellation of devastating symptoms, but it did not provide a cure. As BioMarin’s Chief Scientific Officer, Kevin Eggan, Ph.D., noted, "For many families, a ReNU diagnosis can finally provide answers, but currently there are no approved medicines that address the underlying cause of the disease."

ReNU syndrome is caused by variants in the RNU4-2 gene, a non-coding gene that plays a crucial role in RNA splicing—the cellular process that correctly assembles genetic instructions to produce proteins. When this process is disrupted, it can have catastrophic effects on development, particularly in the brain. Patients often present with moderate-to-severe developmental delays, intellectual disability, microcephaly (abnormally small head), epilepsy, and poor or absent speech. The condition is projected to be one of the leading single-gene causes of developmental delay, with an estimated global population of approximately 100,000 individuals.

The diagnostic challenge is significant. Because RNU4-2 is a non-coding gene, its variants are often missed by standard exome sequencing, which focuses on protein-coding genes. A definitive diagnosis typically requires whole-genome sequencing, a more comprehensive but less common tool. Despite these hurdles, the rapid formation of patient advocacy groups like ReNU Syndrome United highlights the community's urgent need for connection, information, and, most importantly, therapeutic options.

The Science of Hope: An Antisense Approach

The collaboration’s strategy centers on a cutting-edge technology known as antisense oligonucleotides, or ASOs. These are short, synthetic strands of nucleic acids engineered to bind to specific RNA molecules and modify their function. In the case of ReNU syndrome, the ASO candidate is designed to target the genetic variant responsible for about 75% of cases, aiming to correct the faulty splicing mechanism and restore normal cellular function.

This isn't uncharted territory for genetic medicine. ASO technology has already produced transformative results in other severe neurological disorders. The most well-known success is nusinersen (Spinraza), a treatment for spinal muscular atrophy (SMA) that works by modifying RNA splicing to increase the production of a vital protein. The success in SMA provides a powerful proof-of-concept for applying a similar strategy to ReNU syndrome.

The scientific rationale is compelling. By directly targeting the root genetic cause at the RNA level, ASO therapy holds the potential to be a disease-modifying treatment rather than one that simply manages symptoms. While challenges in drug development remain, particularly concerning delivery to the central nervous system and long-term safety, the precision of the ASO platform offers a clear and promising path forward.

A Blueprint for Innovation: The Biotech-Nonprofit Symbiosis

Perhaps as significant as the science is the structure of the partnership itself. It represents a powerful new model for accelerating drug development for rare diseases. The n-Lorem Foundation, founded by ASO pioneer Dr. Stanley T. Crooke, operates with a unique charitable mission: to develop individualized ASO medicines for patients with "nano-rare" diseases, typically affecting 30 or fewer people worldwide.

However, the ReNU syndrome program, while initiated by n-Lorem, represents a condition with a far larger patient population. This is where the symbiotic relationship with BioMarin comes into play. n-Lorem provides the initial, highly specialized ASO discovery and early development expertise, de-risking the program. BioMarin then brings its formidable resources—clinical development infrastructure, regulatory experience, and global commercial reach—to scale the program for a larger patient community.

"Our commitment is to develop ASO medicines and, when we recognize the opportunity to support even more individuals, identify a partner that can advance our medicines to be commercially approved," said Stanley T. Crooke, M.D., Ph.D., Founder, Chairman and CEO of n-Lorem. This model allows the foundation to stay true to its core mission while ensuring promising therapies for more common rare diseases don't languish in early-stage research.

For BioMarin, a company built on commercializing therapies for genetically defined conditions, the partnership is a strategic masterstroke. It provides access to a validated therapeutic platform and a first-in-disease candidate for a substantial rare disease market, reinforcing its leadership position. This alliance effectively creates a pipeline from the frontiers of non-profit research directly into a large-scale commercial development engine.

Charting the Commercial and Clinical Frontier

From an investor's perspective, the collaboration addresses a significant unmet need within a surprisingly large market. With an estimated 100,000 patients worldwide and no existing treatments, a successful therapy for ReNU syndrome represents a major commercial opportunity. This venture allows BioMarin to enter an untapped market with a significant first-mover advantage, leveraging a technology that aligns perfectly with its core focus on genetic science.

The preclinical studies to be conducted jointly by both organizations will be the critical next step, leading to the selection of a lead candidate to advance into human trials. The journey from a press release to an approved medicine is long and fraught with risk, a fact BioMarin acknowledges in its forward-looking statements. However, the combined strengths of n-Lorem's targeted science and BioMarin's development prowess create a formidable force.

This partnership does more than just offer hope for one disease community; it provides a potential blueprint for the entire rare disease ecosystem. By bridging the gap between ultra-rare, non-profit-led research and large-scale commercialization, this model could unlock a new wave of therapies for countless patients who have been waiting for science to catch up to their diagnosis.